Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAY301 in Advanced or Metastatic Solid Tumors
NCT06752681Phase 1Recruiting
- Sponsor
- Day One Biopharmaceuticals
- Start
- Nov 2024
- Primary completion
- Dec 2027
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of DAY301 in solid tumor, sponsored by Day One Biopharmaceuticals. Primary endpoints: Dose Limiting Toxicities at 21 days, Adverse Events and Serious Adverse Events at 12 months and 3 more. Started Nov 2024; status: recruiting.
02
Drugs
DAY301
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06752681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06752681.